

<u>Short Name</u>	<u>Comments</u>	<u>Type</u>	<u>Investigator</u>	<u>Contact</u>
Glioma Registry	Glioma Data Registry for Research	Registry	<b>SHORE:</b> Dr. Todd Vitaz	researchassist@spectrumhealth.org
2015-175	NMTRC012 - PEDS-PLAN – Pediatric Precision Laboratory Advanced Neuroblastoma Therapy- A Pilot Study Using Molecular Guided Therapy with Induction Chemotherapy followed by maintenance with DFMO for Subjects with Newly Diagnosed High-Risk Neuroblastoma	Treatment	<b>SHORE:</b> Dr. Deanna Mitchell	Mary Durston <a href="mailto:Mary.Durston@helendevoschildrens.org">Mary.Durston@helendevoschildrens.org</a> (616) 486-2051
2016-258	HEAD START 4 PROTOCOL: Newly Diagnosed Children (Less than 10 Years Old) With Medulloblastoma and Other Central Nervous System Embryonal Tumors. Clinical and Molecular Risk-Tailored Intensive and Compressed Induction Chemotherapy Followed by Consolidation with Randomization to Either Single-Cycle or to Three Sequential Cycles of Marrow-Ablative Chemotherapy with Autologous Hematopoietic Progenitor Cell Rescue	Treatment	<b>SHORE:</b> Dr. Albert Cornelius	Mary Durston <a href="mailto:Mary.Durston@helendevoschildrens.org">Mary.Durston@helendevoschildrens.org</a> (616) 486-2051
	A Phase II Study of Metronomic and Targeted Anti-angiogenesis Therapy for Children with Recurrent/progressive Medulloblastoma	Treatment	<b>SHORE:</b> Dr. Rebecca Loret de Mola	Mary Durston <a href="mailto:Mary.Durston@helendevoschildrens.org">Mary.Durston@helendevoschildrens.org</a> (616) 486-2051
NRG BN003	Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma	Treatment	<b>CRCWM</b> Physician Investigators	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>

A071401	<b>A Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations</b>	Treatment	<b>CRCWM</b> Physician Investigators	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
ACNS1721	<b>A Phase 2 Study of Veliparib (ABT-888, IND # 139199) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients with Newly Diagnosed High-Grade Glioma (HGG) without H3 K27M or BRAFV600E Mutations</b>	Treatment	<b>CRCWM</b> Physician Investigators	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
ACNS1723	<b>Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients with Newly Diagnosed High Grade Glioma</b>	Treatment	<b>CRCWM</b> Physician Investigators	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
A071701	<b>Genomically-guided Treatment Trial in Brain Metastases</b>	Treatment	<b>CRCWM</b> Physician Investigators	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
URCC 19085	<b>A Phase II Clinical trial with Wireless Transcutaneous Electrical Nerve Stimulation (TENS) for Chemotherapy-induced Peripheral Neuropathy</b>	Treatment	<b>CRCWM</b> Physician Investigators	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
ACNS1422	<b>A Phase II Study of Reduced Therapy for Newly Diagnosed Average-risk WNT-Driven Medulloblastoma Patients</b>	Treatment	<b>CRCWM</b> Physician Investigators	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>